Stable CAD (Coronary artery disease)

Find all the latest content on stable coronary artery disease (stable CAD) published on this website.

A complex and changing disease state requiring wide expertise, stable CAD can involve a diverse range of underlying chronic or evolutionary stages involving full use of all available tools, devices and techniques like those for invasive imaging and functional assessment. Taking into account underlying comorbidities such as diabetes is critical. Advances in imaging techniques, as well as the use of adjunctive pharmacotherapy, vascular access or invasive interventions such as bypass surgery, are important, as are understanding bleeding risks, all of which can be found here…

Filtered By
Stable CAD

237 results

Insights from the ORBITA trial

ORBITA is a blinded, multicentre randomised trial of PCI versus a placebo procedure for angina relief. Find more about the findings with 2 editorials recently published in EuroIntervention Journal.

Randomised Trials in FFR and PCI

On this page you will find a list of randomised trials in FFR and PCI published in some of the world's top cardiology and interventional cardiology journals.

OCT Atlas app – The second edition is out!

Developed specifically for the iPad, The Clinical Atlas of OCT offers a rapid and interactive guidance to a systematic and scientifically critical interpretation of OCT images for interventional cardiologists, pathologists, and other physicians, technicians, trainees and research staff.

 
Supported by an unrestricted educational grant from

Outcomes after angiography with sodium bicarbonate and acetylcysteine

28 Nov 2017

Francesco Costa

Reviewer

Francesco Costa

Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

Clinical outcomes and cost-effectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease

20 Nov 2017

Three-year follow-up of the FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation).

Dejan Milasinovic

Reviewer

Dejan Milasinovic

Risk of early adverse events after Clopidogrel discontinuation in patients undergoing short-term Dual Antiplatelet Therapy: An individual participant data analysis

11 Oct 2017

Giuseppe Di Gioia

Reviewer

Giuseppe Di Gioia

2017 ESC Focused update on Dual Antiplatelet Therapy (DAPT)

04 Sep 2017

As dual antiplatelet therapy (DAPT) seems to have been interventionalists’ close companion since the pioneering studies showing its benefits over oral anticoagulants (OAC) some 20 years ago, the myriad of ensuing studies has led to expanding indications, but has also uncovered the inherent risks of DAPT. In the 2017 Focused Update, the hitherto accumulated evidence is eloquently summarized into a set of recommendations that provide guidance on some of the important questions of an interventional cardiologist's everyday practice: which of the currently available P2Y12 inhibitors should be selected, what is the optimal duration of DAPT and how to manage bleeding complications.

Dejan Milasinovic

Author

Dejan Milasinovic

Ticagrelor or clopidogrel in DAPT for acute coronary syndromes: A call for a stepwise approach?

Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study

28 Aug 2017

Christopher Cook

Reviewer

Christopher Cook